DermRx.
← All drugs

nemolizumab

Nemluvio

Modality
mAb (humanized IgG2)
Mechanism
IL-31 receptor A antagonist — itch pathway
Targets
IL-31Rα
Storage
refrigerated 2–8 °C
Approved
prurigo nodularis — FDA 2024 · atopic dermatitis — FDA 2024
In trial
—
Sources
DailyMed (FDA label)ClinicalTrials.gov
Last verified
2026-04-14
No curated MOA diagram yet. See lib/moa-data.ts for the shape; add an entry keyed by nemolizumab.

Monitoring & workup

Baseline workup

  • •TB IGRA (or PPD)
  • •HBV sAg if high risk; HCV Ab if high risk
  • •Update age-appropriate vaccines before start

Ongoing monitoring

  • •No routine labs
  • •Annual TB screening if high exposure risk
  • •IL-17 class: monitor for candida overgrowth + IBD flare
  • •IL-23 class: monitor for injection-site reactions